Literature DB >> 18807212

Serum levels of angiogenic factors and their prognostic relevance in bladder cancer.

Tibor Szarvas1, Tobias Jäger, Falk Droste, Markus Becker, Ilona Kovalszky, Imre Romics, Süleyman Ergün, Herbert Rübben.   

Abstract

Angiogenesis plays a critical role in tumor growth. VEGF, angiopoietins (Ang-1, Ang-2) and their tyrosine kinase receptor Tie2 are major regulators of angiogenesis. The aim of this study was to evaluate the prognostic value of the serum levels of these factors in bladder cancer. We analyzed the serum samples of 117 bladder cancer patients and 64 healthy volunteers by enzyme linked immunosorbent assay (ELISA) for Ang-1, Ang-2, VEGF and the extracellular domain of Tie2. The statistical evaluation of the obtained data was performed via Kaplan-Meier log-rank test, univariate Cox analyses as well as Cox proportional hazards regression model. Serum Ang-1 levels of bladder cancer patients were significantly higher (p < 0.001), while soluble Ang-2 and Tie2 levels were significantly lower (p = 0.016 and p = 0.001 respectively) in patients than those in controls. Cox univariate analysis revealed high sTie2 serum level as a risk factor for metastasis and as a borderline significant risk factor for disease related death (p = 0.022 and p = 0.081 respectively). These correlations were independent from tumor stage and grade in a Cox multivariate model (p = 0.016 and p = 0.069). These data indicate that the serum levels of analyzed angiogenic factors do change characteristically in bladder cancer. The soluble extracellular serum level of Tie2 may provide a stage and grade independent diagnostic tool to select a high risk group of bladder cancer patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18807212     DOI: 10.1007/s12253-008-9107-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  32 in total

1.  Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.

Authors:  A L Harris; P Reusch; B Barleon; C Hang; N Dobbs; D Marme
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

2.  Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder.

Authors:  W D Beecken; T Engl; Judith Hofmann; D Jonas; R Blaheta
Journal:  J Cell Mol Med       Date:  2005 Jul-Sep       Impact factor: 5.310

3.  Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer.

Authors:  M Volm; R Koomägi; J Mattern
Journal:  Int J Cancer       Date:  1997-02-20       Impact factor: 7.396

4.  Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival.

Authors:  Christian Sfiligoi; Annarita de Luca; Ilaria Cascone; Valentina Sorbello; Luca Fuso; Riccardo Ponzone; Nicoletta Biglia; Enrica Audero; Riccardo Arisio; Federico Bussolino; Piero Sismondi; Michele De Bortoli
Journal:  Int J Cancer       Date:  2003-02-10       Impact factor: 7.396

Review 5.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

Authors:  J Holash; S J Wiegand; G D Yancopoulos
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

6.  Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer.

Authors:  Natsuo Oka; Yasuyo Yamamoto; Masayuki Takahashi; Masaaki Nishitani; Hiro-Omi Kanayama; Susumu Kagawa
Journal:  BJU Int       Date:  2005-03       Impact factor: 5.588

7.  Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.

Authors:  A Papapetropoulos; G García-Cardeña; T J Dengler; P C Maisonpierre; G D Yancopoulos; W C Sessa
Journal:  Lab Invest       Date:  1999-02       Impact factor: 5.662

Review 8.  Angiopoietins in tumours: the angiogenic switch.

Authors:  Catherine R Tait; Pamela F Jones
Journal:  J Pathol       Date:  2004-09       Impact factor: 7.996

9.  Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.

Authors:  J P Crew; S Fuggle; R Bicknell; D W Cranston; A de Benedetti; A L Harris
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

Review 10.  Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2.

Authors:  Claire E Lewis; Michele De Palma; Luigi Naldini
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

View more
  12 in total

1.  CT perfusion in solid-body tumours. Part I: Technical issues.

Authors:  G Petralia; L Preda; G D'Andrea; S Viotti; L Bonello; R De Filippi; M Bellomi
Journal:  Radiol Med       Date:  2010-02-22       Impact factor: 3.469

2.  Body mass and smoking are modifiable risk factors for recurrent bladder cancer.

Authors:  Asaf Wyszynski; Sam A Tanyos; Judy R Rees; Carmen J Marsit; Karl T Kelsey; Alan R Schned; Eben M Pendleton; Maria O Celaya; Michael S Zens; Margaret R Karagas; Angeline S Andrew
Journal:  Cancer       Date:  2013-10-10       Impact factor: 6.860

3.  [Plasma E-cadherin levels in urinary bladder cancer: does it improve risk stratification?].

Authors:  T Szarvas; F Hoffmann; M Becker; M Schenck; F Vom Dorp; H Rübben; T Jäger
Journal:  Urologe A       Date:  2011-01       Impact factor: 0.639

Review 4.  CT perfusion in oncology: how to do it.

Authors:  G Petralia; L Bonello; S Viotti; L Preda; G d'Andrea; M Bellomi
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

5.  A multiplexed analysis approach identifies new association of inflammatory proteins in patients with overactive bladder.

Authors:  Emily Ma; Joel Vetter; Laura Bliss; H Henry Lai; Indira U Mysorekar; Sanjay Jain
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-30

Review 6.  [Urine-based markers of angiogenesis in bladder cancer].

Authors:  M Becker; D Tilki; T Szarvas; H Rübben; S Ergün
Journal:  Urologe A       Date:  2009-06       Impact factor: 0.639

7.  Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells.

Authors:  Cheol Yong Yoon; Jung Sun Lee; Bo Sun Kim; Seong Jin Jeong; Sung Kyu Hong; Seok Soo Byun; Sang Eun Lee
Journal:  Korean J Urol       Date:  2011-01-24

8.  Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables.

Authors:  Jan Rykala; Karolina Przybylowska; Ireneusz Majsterek; Grazyna Pasz-Walczak; Andrzej Sygut; Adam Dziki; Julia Kruk-Jeromin
Journal:  Pathol Oncol Res       Date:  2011-05-11       Impact factor: 3.201

9.  Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro.

Authors:  Jin Wen; Han-Zhong Li; Zhi-Gang Ji; Jing Jin
Journal:  Cancer Cell Int       Date:  2015-02-28       Impact factor: 5.722

10.  Expression of angiogenesis regulatory proteins and epithelial-mesenchymal transition factors in platelets of the breast cancer patients.

Authors:  Hui Han; Fang-Li Cao; Bao-Zhong Wang; Xue-Ru Mu; Guang-Yao Li; Xiu-Wen Wang
Journal:  ScientificWorldJournal       Date:  2014-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.